Nicholas Saraceno, Editor

In an interview with Nico Saraceno at DPHARM 2024, Munther Baara, VP strategy and innovation, EDETEK touches on the features an effective AI/ML model can provide and how they benefit data management in trials.

In an interview with Nico Saraceno at DPHARM 2024, Pellegrino highlights current challenges she is seeing in patient recruitment and the use of technology to identify patients.

Session provides insight as to how to boost interoperability and expand the middleware on a global scale.

Panel discusses the advantages that these models can provide in adding efficiencies to the clinical trial process.

In an interview with Nico Saraceno at DPHARM 2024, Smith discusses how predictive modeling and community engagement can increase diversity.

According to the session panelists, tackling challenges and finding efficiencies is imperative for success.

The presentation expresses the importance of putting the patient at the center of patient recruitment.

Session reveals how organizations can implement DCTs into their clinical trial planning and execution processes.

Datopotamab deruxtecan, the first TROP2-directed DXd antibody drug conjugate, is being evaluated for locally advanced or metastatic nonsquamous non-small cell lung cancer.

The drug development process, beginning with preclinical research up to when the product goes to market, requires time, risk, and high costs.

Because artificial intelligence use in healthcare is powered by patient data, it is imperative to guard privacy by verifying that security measures are in place to protect against any data breaches.

Study highlights efficacy of effectively monitoring attention-deficit hyperactivity disorder treatment effects with Qbtest.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.

Panel explores challenges that could affect their development.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.

Session explores practicality of models for selling low-cost drugs.

Speakers dive into the importance of risk-based methods and central-monitoring solutions as they pertain to these trials.